摘要
目的探讨瑞舒伐他汀联合复方丹参治疗冠心病合并高胆固醇血症患者的效果及其对载脂蛋白A1（Apo A1）、载脂蛋白B（Apo B）和脂蛋白酯酶水平的影响。方法选取2011年3月~2015年6月四川省人民医院崇州分院诊治的82例冠心病合并高胆固醇血症患者为研究对象,根据治疗方案的不同分为瑞舒伐他汀组（单独组）和瑞舒伐他汀＋复方丹参组（联合组）,每组各41例,比较两组心功能、血脂、氧化指标、六分钟步行试验阳性率、Apo A1、Apo B和脂蛋白酯酶水平。结果联合组治疗后的血脂指标均明显降低（P〈0.05）;与单独组比较,联合组血脂指标的降低幅度更为显著（P〈0.05）。联合组治疗后六分钟步行试验阳性率为29.27%,显著低于单独组的48.78%（P〈0.05）。单独组心绞痛发生次数为（3.51±0.76）次,显著高于联合组的（1.88±0.55）次（P〈0.01）。两组不良反应发生率比较差异无统计学意义（P〉0.05）。两组治疗后心输出量（CO）和左室射血分数（LVEF）明显升高（P〈0.05）,心脏指数（CI）和左室舒张末内径（LVEDD）差异无统计学意义（P〉0.05）;联合组治疗后CO和LVEF的增加幅度明显优于单独组（P〈0.05）。联合组治疗后氧化型低密度脂蛋白（ox-LDL）、丙二醛（MDA）、超氧化物歧化酶（SOD）及Apo A1、Apo B和脂蛋白酯酶水平的改善程度均较单独组明显（P〈0.05）。结论瑞舒伐他汀联合复方丹参可提高冠心病合并高胆固醇血症的临床疗效,改善患者心功能,降低血脂、Apo A1、Apo B和脂蛋白酯酶水平。
Objective To explore effect of Rosuvastatin combined with Danshen Compound in the treatment of coronary heart disease with hypercholesterolemia and influence on the levels of Apo A1, Apo B and lipoprotein lipase. Methods82 cases of coronary heart disease with hypercholesterolemia from March 2011 to June 2015 at Chongzhou Branch of Sichuan Provincial People′ s Hospital were selected as research objects. The patients were randomly divided into two groups according to different treatment regimens： Rosuvastatin group（single group） and Danshen Compound plus Rosuvastatin group（combined group）, each group had 41 cases. The cardiac function, blood lipids, oxidative indexes, 6minutes walk test positive rate, Apo A1, Apo B and lipoprotein lipase levels were compared between two groups. Results After treatment, the serum lipids indicators were significantly decreased in combined group（P 〈 0.05）, reduction of serum lipids indicators in combined group were more significant than those in single group（P 〈 0.05）. After treatment,6 minutes walk test positive rate of combined group was 29.27%, significantly lower than that of single group（48.78%）（P 〈 0.05）. Angina pectoris occurrence of single group was（3.51±0.76） times, significantly higher than that of combined group [（1.88±0.55） times]（P 〈 0.01）. There was no significant difference on incidence rate of adverse reaction between two groups（P 〉 0.05）. After treatment,cardiac output（CO） and left ventricular ejection fraction（LVEF） of two groups were significantly increased（P 〈 0.05）, while cardiac index（CI） and left ventricular end diastolic diameter（LVEDD） were no significant differences（P 〉 0.05）. Increase amplitude in combined group after treatment was superior to single group（P 〈 0.05）. Improvement on the contents of ox-LDL, malondialdehyde（MDA）, superoxide dismutase（SOD）, Apo A1, Apo B and lipoprotein lipase in combined group were more obvious than those in single group（P 〈0.05）. Conclusion Rosuvastatin combined with Danshen Compound can enhance clinical efficacy on the treatment of coronary heart disease with hypercholesterolemia, improve heart function of patients, reduce the level of lipids, Apo A1,apo B and lipoprotein lipase.
出处
《中国医药导报》
CAS
2016年第7期123-126,共4页
China Medical Herald
基金
四川省卫生和计划生育委员会科研课题立项项目(150096)
关键词
瑞舒伐他汀
复方丹参
冠心病
高胆固醇血症
Rosuvastatin
Danshen Compound
Coronary heart disease
Hypercholesterolemia
